133 related articles for article (PubMed ID: 29216393)
1. MONTE CARLO SIMULATION OF OUT-OF-FIELD ORGAN DOSES AND CANCER RISK IN TANZANIA FOR RADIATION THERAPY OF UNILATERAL RETINOBLASTOMA USING A 60Co UNIT.
Suleiman SA; Qi Y; Pi Y; George Xu X
Radiat Prot Dosimetry; 2018 May; 179(3):263-270. PubMed ID: 29216393
[TBL] [Abstract][Full Text] [Related]
2. Monte carlo study of organ doses and related risk for cancer in Tanzania from scattered photons in cervical radiation treatment involving Co-60 source.
Suleiman SA; Qi Y; Chen Z; Xu XG
Phys Med; 2019 Jun; 62():13-19. PubMed ID: 31153393
[TBL] [Abstract][Full Text] [Related]
3. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo study of organ doses and related risk for cancer in Algeria from scattered neutrons in prostate treatment involving 3D-CRT.
Alem-Bezoubiri A; Suleiman SA; Behidj I; Mazrou H; Chami AC
Appl Radiat Isot; 2022 Feb; 180():110065. PubMed ID: 34933226
[TBL] [Abstract][Full Text] [Related]
5. EVALUATION OF SECONDARY DOSE AND CANCER RISK FOR OUT-OF-FIELD ORGAN IN ESOPHAGEAL CANCER IMRT IN A CHINESE HOSPITAL USING ATOM PHANTOM MEASUREMENTS.
Qi Y; He L; Wang Z; Liu Y; Liu H; Huo W; Xu XG; Chen Z
Radiat Prot Dosimetry; 2017 Dec; 177(4):389-396. PubMed ID: 28472430
[TBL] [Abstract][Full Text] [Related]
6. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
7. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2018 Oct; 45(10):4775-4782. PubMed ID: 30105825
[TBL] [Abstract][Full Text] [Related]
8. A critical evaluation of secondary cancer risk models applied to Monte Carlo dose distributions of 2-dimensional, 3-dimensional conformal and hybrid intensity-modulated radiation therapy for breast cancer.
Joosten A; Bochud F; Moeckli R
Phys Med Biol; 2014 Aug; 59(16):4697-722. PubMed ID: 25082795
[TBL] [Abstract][Full Text] [Related]
9. Calculating and estimating second cancer risk from breast radiotherapy using Monte Carlo code with internal body scatter for each out-of-field organ.
Takata T; Shiraishi K; Kumagai S; Arai N; Kobayashi T; Oba H; Okamoto T; Kotoku J
J Appl Clin Med Phys; 2020 Dec; 21(12):62-73. PubMed ID: 33128332
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
11. Out-of-field doses from secondary radiation produced in proton therapy and the associated risk of radiation-induced cancer from a brain tumor treatment.
Ardenfors O; Dasu A; Lillhök J; Persson L; Gudowska I
Phys Med; 2018 Sep; 53():129-136. PubMed ID: 30241747
[TBL] [Abstract][Full Text] [Related]
12. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma.
Mazonakis M; Berris T; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2014 May; 41(5):051702. PubMed ID: 24784368
[TBL] [Abstract][Full Text] [Related]
13. Organ-specific radiation-induced cancer risk estimates due to radiotherapy for benign pigmented villonodular synovitis.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Phys Med Biol; 2016 Sep; 61(17):6400-12. PubMed ID: 27499236
[TBL] [Abstract][Full Text] [Related]
14. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy.
Bezak E; Takam R; Yeoh E; Marcu LG
Phys Med; 2017 Oct; 42():253-258. PubMed ID: 28302493
[TBL] [Abstract][Full Text] [Related]
15. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age.
Zacharatou Jarlskog C; Paganetti H
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):228-35. PubMed ID: 18571337
[TBL] [Abstract][Full Text] [Related]
16. Supplemental computational phantoms to estimate out-of-field absorbed dose in photon radiotherapy.
Gallagher KJ; Tannous J; Nabha R; Feghali JA; Ayoub Z; Jalbout W; Youssef B; Taddei PJ
Phys Med Biol; 2018 Jan; 63(2):025021. PubMed ID: 29099727
[TBL] [Abstract][Full Text] [Related]
17. Comparison of whole-body phantom designs to estimate organ equivalent neutron doses for secondary cancer risk assessment in proton therapy.
Moteabbed M; Geyer A; Drenkhahn R; Bolch WE; Paganetti H
Phys Med Biol; 2012 Jan; 57(2):499-515. PubMed ID: 22217682
[TBL] [Abstract][Full Text] [Related]
18. Special radiobiological features of second cancer risk after particle radiotherapy.
Trott KR
Phys Med; 2017 Oct; 42():221-227. PubMed ID: 29103987
[TBL] [Abstract][Full Text] [Related]
19. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.
Wong FL; Boice JD; Abramson DH; Tarone RE; Kleinerman RA; Stovall M; Goldman MB; Seddon JM; Tarbell N; Fraumeni JF; Li FP
JAMA; 1997 Oct; 278(15):1262-7. PubMed ID: 9333268
[TBL] [Abstract][Full Text] [Related]
20. A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models.
Bednarz B; Athar B; Xu XG
Med Phys; 2010 May; 37(5):1987-94. PubMed ID: 20527532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
